Last reviewed · How we verify
Destin Maximum Strength 40% Zinc
Zinc oxide forms a physical barrier on the skin surface to protect against moisture and irritants, reducing diaper rash and promoting skin healing.
Zinc oxide forms a physical barrier on the skin surface to protect against moisture and irritants, reducing diaper rash and promoting skin healing. Used for Diaper rash prevention and treatment, Minor skin irritation and chafing.
At a glance
| Generic name | Destin Maximum Strength 40% Zinc |
|---|---|
| Also known as | Destin |
| Sponsor | University of the Philippines |
| Drug class | Topical skin protectant |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Zinc oxide is a topical protectant that creates an occlusive barrier on the skin, preventing contact between irritants (urine, feces) and the epidermis. It also has mild astringent and antiseptic properties that support skin integrity and reduce inflammation in diaper dermatitis. The 40% concentration provides enhanced protective coverage for affected areas.
Approved indications
- Diaper rash prevention and treatment
- Minor skin irritation and chafing
Common side effects
- Local skin irritation
- Allergic contact dermatitis
Key clinical trials
- Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants (PHASE4)
- Treatment of Incontinence Associated Dermatitis in Older Children and Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Destin Maximum Strength 40% Zinc CI brief — competitive landscape report
- Destin Maximum Strength 40% Zinc updates RSS · CI watch RSS
- University of the Philippines portfolio CI